Research Feeds

View All
Characterizing the gut microbiota in females with infertility and preliminary results of a water-soluble dietary fiber intervention study A prebiotic dietary pilot intervention restores faecal metabolites and may be neuroprotective in Parkinson’s Disease Diagnosis of the menopause: NICE guidance and quality standards Causes of Death in End-Stage Kidney Disease: Comparison Between the United States Renal Data System and a Large Integrated Health Care System Factors affecting the absorption and excretion of lead in the rat Factors associated with age at menarche, menstrual knowledge, and hygiene practices among schoolgirls in Sharjah, UAE Cadmium transport in blood serum The non-pathogenic Escherichia coli strain Nissle 1917 – features of a versatile probiotic Structured Exercise Benefits in Euthyroid Graves’ Disease: Improved Capacity, Fatigue, and Relapse Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson’s Disease A Pilot Microbiota Study in Parkinson’s Disease Patients versus Control Subjects, and Effects of FTY720 and FTY720-Mitoxy Therapies in Parkinsonian and Multiple System Atrophy Mouse Models Dysbiosis of the Saliva Microbiome in Patients With Polycystic Ovary Syndrome Integrated Microbiome and Host Transcriptome Profiles Link Parkinson’s Disease to Blautia Genus: Evidence From Feces, Blood, and Brain Gut microbiota modulation: a narrative review on a novel strategy for prevention and alleviation of ovarian aging Long-term postmenopausal hormone therapy and endometrial cancer

GS2 Gallium Complex: A Novel Inhibitor of MMP-14 for Anti-Metastatic Cancer Therapy Original paper

March 18, 2025

  • Metals
    Metals

    Heavy metals play a significant and multifaceted role in the pathogenicity of microbial species.

  • Women’s Health
    Women’s Health

    Women’s health, a vital aspect of medical science, encompasses various conditions unique to women’s physiological makeup. Historically, women were often excluded from clinical research, leading to a gap in understanding the intricacies of women’s health needs. However, recent advancements have highlighted the significant role that the microbiome plays in these conditions, offering new insights and potential therapies. MicrobiomeSignatures.com is at the forefront of exploring the microbiome signature of each of these conditions to unravel the etiology of these diseases and develop targeted microbiome therapies.

Last Updated: 2024-06-23

Microbiome Signatures identifies and validates condition-specific microbiome shifts and interventions to accelerate clinical translation. Our multidisciplinary team supports clinicians, researchers, and innovators in turning microbiome science into actionable medicine.

Karen Pendergrass

Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease—four years before the first published case study.

What Was Studied?

This study examined the effects of [N-(5-chloro-2-hydroxyphenyl)-L-aspartato] chlorogallate (GS2), a water-soluble gallium complex, on tumor cell invasion and the activity and expression of matrix metalloproteinases (MMPs). Specifically, it evaluated GS2’s anti-invasive properties and its regulatory effects on MMP-2, MMP-9, and MMP-14 in two human cancer cell lines: metastatic HT-1080 fibrosarcoma and MDA-MB231 breast carcinoma cells.

Who Was Studied?

The research utilized human cell lines HT-1080 (fibrosarcoma) and MDA-MB231 (breast carcinoma). Additionally, MCF7 cells transfected with MMP-14 and non-transfected fibroblast cells (F40) were used for supplemental experiments.

Most Important Findings

GS2 demonstrated significant anti-invasive and anti-MMP activities at non-cytotoxic concentrations. The compound inhibited MMP-2, MMP-9, and MMP-14 activities in a dose-dependent manner, with IC50 values of 168 µM, 82 µM, and 20 µM, respectively. GS2 reduced the mRNA expression of MMP-14 in both cell lines and inhibited MMP-2 and MMP-9 expression exclusively in MDA-MB231 cells. Western blotting confirmed decreased MMP-14 protein expression in response to GS2. Importantly, GS2 significantly inhibited cell invasion through a type-I collagen-coated matrix, correlating with the downregulation of MMP-14, a critical regulator of the extracellular matrix and tumor invasion. Notably, GS2’s inhibition of MMP-14 showed specificity for cells expressing higher MMP-14 levels, a hallmark of invasive cancer phenotypes.

Greatest Implications

The findings suggest GS2 is a promising candidate for anti-metastatic therapy targeting MMP-14. This is particularly relevant for cancers characterized by elevated MMP-14 expression, such as type II endometrial adenocarcinoma and invasive pituitary adenomas. GS2’s ability to selectively inhibit MMP-14 and reduce cancer cell invasion positions it as a potential therapeutic for limiting tumor metastasis. Moreover, its low cytotoxicity at effective concentrations highlights its clinical applicability.

Matrix Metalloproteinases (MMPs)

Matrix Metalloproteinases (MMPs) are zinc-dependent enzymes that regulate extracellular matrix remodeling, with critical roles in health, disease, and interactions with the microbiome.

Join the Roundtable

Contribute to published consensus reports, connect with top clinicians and researchers, and receive exclusive invitations to roundtable conferences.